Asset Management - Income
Compare Stocks
5 / 10Stock Comparison
NXC vs BLK vs IVZ vs TROW vs BEN
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Asset Management
Asset Management
Asset Management
NXC vs BLK vs IVZ vs TROW vs BEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Asset Management - Income | Asset Management | Asset Management | Asset Management | Asset Management |
| Market Cap | $86M | $165.65B | $11.92B | $22.54B | $15.86B |
| Revenue (TTM) | $4M | $20.41B | $6.38B | $7.31B | $8.77B |
| Net Income (TTM) | $7M | $6.10B | $-243M | $2.09B | $812M |
| Gross Margin | 100.0% | 49.4% | 43.2% | 62.7% | 80.3% |
| Operating Margin | 90.8% | 37.1% | -10.9% | 29.9% | 6.9% |
| Forward P/E | 38.0x | 20.1x | 10.4x | 11.2x | 11.2x |
| Total Debt | $6K | $14.22B | $10.12B | $860M | $13.30B |
| Cash & Equiv. | $391K | $12.76B | $1.98B | $3.38B | $3.57B |
NXC vs BLK vs IVZ vs TROW vs BEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Jan 26 | Return |
|---|---|---|---|
| Nuveen California S… (NXC) | 100 | 85.8 | -14.2% |
| BlackRock, Inc. (BLK) | 100 | 202.5 | +102.5% |
| Invesco Ltd. (IVZ) | 100 | 329.6 | +229.6% |
| T. Rowe Price Group… (TROW) | 100 | 84.7 | -15.3% |
| Franklin Resources,… (BEN) | 100 | 126.6 | +26.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NXC vs BLK vs IVZ vs TROW vs BEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NXC carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.
- Lower volatility, beta 0.04, Low D/E 0.0%, current ratio 4.13x
- Efficiency ratio 0.1% vs BEN's 0.7% (lower = leaner)
- Beta 0.04 vs IVZ's 1.67, lower leverage
- Efficiency ratio 0.1% vs BEN's 0.7%
BLK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 14.3%, EPS growth 15.1%
- 245.8% 10Y total return vs BEN's 23.5%
- 14.3% NII/revenue growth vs NXC's -28.6%
- 1.9% yield, 15-year raise streak, vs TROW's 4.9%, (1 stock pays no dividend)
IVZ ranks third and is worth considering specifically for value and momentum.
- Lower P/E (10.4x vs 11.2x)
- +93.1% vs NXC's +4.2%
TROW is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 3 yrs, beta 1.18, yield 4.9%
- Beta 1.18, yield 4.9%, current ratio 73.08x
- NIM 3.4% vs BLK's 0.2%
Among these 5 stocks, BEN doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.3% NII/revenue growth vs NXC's -28.6% | |
| Value | Lower P/E (10.4x vs 11.2x) | |
| Quality / Margins | Efficiency ratio 0.1% vs BEN's 0.7% (lower = leaner) | |
| Stability / Safety | Beta 0.04 vs IVZ's 1.67, lower leverage | |
| Dividends | 1.9% yield, 15-year raise streak, vs TROW's 4.9%, (1 stock pays no dividend) | |
| Momentum (1Y) | +93.1% vs NXC's +4.2% | |
| Efficiency (ROA) | Efficiency ratio 0.1% vs BEN's 0.7% |
NXC vs BLK vs IVZ vs TROW vs BEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NXC vs BLK vs IVZ vs TROW vs BEN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NXC leads in 2 of 6 categories
IVZ leads 2 • TROW leads 1 • BLK leads 0 • BEN leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NXC leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
BLK is the larger business by revenue, generating $20.4B annually — 5509.5x NXC's $4M. NXC is the more profitable business, keeping 60.7% of every revenue dollar as net income compared to IVZ's -4.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $20.4B | $6.4B | $7.3B | $8.8B |
| EBITDAEarnings before interest/tax | $7M | $8.3B | $1.2B | $2.7B | $1.2B |
| Net IncomeAfter-tax profit | $7M | $6.1B | -$243M | $2.1B | $812M |
| Free Cash FlowCash after capex | $0 | $3.9B | $1.9B | $2.3B | $938M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +49.4% | +43.2% | +62.7% | +80.3% |
| Operating MarginEBIT ÷ Revenue | +90.8% | +37.1% | -10.9% | +29.9% | +6.9% |
| Net MarginNet income ÷ Revenue | +60.7% | +31.2% | -4.4% | +28.5% | +6.0% |
| FCF MarginFCF ÷ Revenue | — | +23.0% | +22.6% | +20.2% | +10.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -88.4% | -22.7% | +34.2% | +3.7% | +100.0% |
Valuation Metrics
IVZ leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 11.2x trailing earnings, TROW trades at a 71% valuation discount to NXC's 38.0x P/E. On an enterprise value basis, TROW's 7.6x EV/EBITDA is more attractive than BEN's 22.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $86M | $165.7B | $11.9B | $22.5B | $15.9B |
| Enterprise ValueMkt cap + debt − cash | $85M | $167.1B | $20.1B | $20.0B | $25.6B |
| Trailing P/EPrice ÷ TTM EPS | 37.97x | 25.42x | -16.77x | 11.20x | 33.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.10x | 10.44x | 11.22x | 11.21x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.13x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 20.62x | 16.34x | 7.64x | 22.53x |
| Price / SalesMarket cap ÷ Revenue | 23.16x | 8.12x | 1.87x | 3.08x | 1.81x |
| Price / BookPrice ÷ Book value/share | 0.96x | 3.28x | 0.94x | 1.92x | 1.11x |
| Price / FCFMarket cap ÷ FCF | — | 35.24x | 8.27x | 15.24x | 17.40x |
Profitability & Efficiency
TROW leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TROW delivers a 17.6% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-2 for IVZ. NXC carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BEN's 0.94x. On the Piotroski fundamental quality scale (0–9), BLK scores 6/9 vs NXC's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.3% | +9.9% | -1.7% | +17.6% | +5.6% |
| ROA (TTM)Return on assets | +8.3% | +3.7% | -0.9% | +14.4% | +2.5% |
| ROICReturn on invested capital | +2.8% | +9.9% | -2.3% | +13.3% | +1.6% |
| ROCEReturn on capital employed | +3.8% | +5.8% | -2.6% | +15.9% | +2.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.00x | 0.29x | 0.78x | 0.07x | 0.94x |
| Net DebtTotal debt minus cash | -$390,878 | $1.5B | $8.1B | -$2.5B | $9.7B |
| Cash & Equiv.Liquid assets | $390,878 | $12.8B | $2.0B | $3.4B | $3.6B |
| Total DebtShort + long-term debt | $6,477 | $14.2B | $10.1B | $860M | $13.3B |
| Interest CoverageEBIT ÷ Interest expense | 85.16x | 9.27x | -6.19x | — | 15.19x |
Total Returns (Dividends Reinvested)
IVZ leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLK five years ago would be worth $13,352 today (with dividends reinvested), compared to $6,915 for TROW. Over the past 12 months, IVZ leads with a +93.1% total return vs NXC's +4.2%. The 3-year compound annual growth rate (CAGR) favors IVZ at 21.6% vs NXC's 3.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.2% | -1.1% | +0.4% | +0.2% | +29.6% |
| 1-Year ReturnPast 12 months | +4.2% | +18.3% | +93.1% | +18.9% | +55.5% |
| 3-Year ReturnCumulative with dividends | +9.7% | +75.7% | +79.8% | +11.5% | +35.3% |
| 5-Year ReturnCumulative with dividends | -3.4% | +33.5% | +8.2% | -30.9% | +7.4% |
| 10-Year ReturnCumulative with dividends | +13.1% | +245.8% | +22.1% | +93.6% | +23.5% |
| CAGR (3Y)Annualised 3-year return | +3.1% | +20.7% | +21.6% | +3.7% | +10.6% |
Risk & Volatility
NXC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NXC is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than IVZ's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NXC currently trades 98.8% from its 52-week high vs BLK's 87.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.04x | 1.28x | 1.67x | 1.18x | 1.31x |
| 52-Week HighHighest price in past year | $13.45 | $1219.94 | $29.61 | $118.22 | $31.44 |
| 52-Week LowLowest price in past year | $12.66 | $914.84 | $14.10 | $85.51 | $20.08 |
| % of 52W HighCurrent price vs 52-week peak | +98.8% | +87.5% | +90.6% | +87.6% | +97.1% |
| RSI (14)Momentum oscillator 0–100 | 60.1 | 61.3 | 69.4 | 78.2 | 78.4 |
| Avg Volume (50D)Average daily shares traded | 0 | 790K | 5.1M | 2.3M | 5.1M |
Analyst Outlook
Evenly matched — BLK and TROW each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: BLK as "Buy", IVZ as "Hold", TROW as "Hold", BEN as "Hold". Consensus price targets imply 22.8% upside for BLK (target: $1312) vs -5.8% for BEN (target: $29). For income investors, TROW offers the higher dividend yield at 4.93% vs BLK's 1.92%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $1311.78 | $29.72 | $101.20 | $28.75 |
| # AnalystsCovering analysts | — | 33 | 28 | 38 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | +1.9% | +3.1% | +4.9% | +4.3% |
| Dividend StreakConsecutive years of raises | — | 15 | 4 | 3 | 6 |
| Dividend / ShareAnnual DPS | — | $20.46 | $0.83 | $5.11 | $1.33 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.2% | +15.6% | +2.8% | +1.5% |
NXC leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). IVZ leads in 2 (Valuation Metrics, Total Returns). 1 tied.
NXC vs BLK vs IVZ vs TROW vs BEN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NXC or BLK or IVZ or TROW or BEN a better buy right now?
For growth investors, BlackRock, Inc.
(BLK) is the stronger pick with 14. 3% revenue growth year-over-year, versus -28. 6% for Nuveen California Select Tax-Free Income Portfolio (NXC). T. Rowe Price Group, Inc. (TROW) offers the better valuation at 11. 2x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate BlackRock, Inc. (BLK) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NXC or BLK or IVZ or TROW or BEN?
On trailing P/E, T.
Rowe Price Group, Inc. (TROW) is the cheapest at 11. 2x versus Nuveen California Select Tax-Free Income Portfolio at 38. 0x. On forward P/E, Invesco Ltd. is actually cheaper at 10. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NXC or BLK or IVZ or TROW or BEN?
Over the past 5 years, BlackRock, Inc.
(BLK) delivered a total return of +33. 5%, compared to -30. 9% for T. Rowe Price Group, Inc. (TROW). Over 10 years, the gap is even starker: BLK returned +245. 8% versus NXC's +13. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NXC or BLK or IVZ or TROW or BEN?
By beta (market sensitivity over 5 years), Nuveen California Select Tax-Free Income Portfolio (NXC) is the lower-risk stock at 0.
04β versus Invesco Ltd. 's 1. 67β — meaning IVZ is approximately 4086% more volatile than NXC relative to the S&P 500. On balance sheet safety, Nuveen California Select Tax-Free Income Portfolio (NXC) carries a lower debt/equity ratio of 0% versus 94% for Franklin Resources, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NXC or BLK or IVZ or TROW or BEN?
By revenue growth (latest reported year), BlackRock, Inc.
(BLK) is pulling ahead at 14. 3% versus -28. 6% for Nuveen California Select Tax-Free Income Portfolio (NXC). On earnings-per-share growth, the picture is similar: BlackRock, Inc. grew EPS 15. 1% year-over-year, compared to -235. 6% for Invesco Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NXC or BLK or IVZ or TROW or BEN?
Nuveen California Select Tax-Free Income Portfolio (NXC) is the more profitable company, earning 60.
7% net margin versus -4. 4% for Invesco Ltd. — meaning it keeps 60. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NXC leads at 90. 8% versus -10. 9% for IVZ. At the gross margin level — before operating expenses — NXC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NXC or BLK or IVZ or TROW or BEN more undervalued right now?
On forward earnings alone, Invesco Ltd.
(IVZ) trades at 10. 4x forward P/E versus 20. 1x for BlackRock, Inc. — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLK: 22. 8% to $1311. 78.
08Which pays a better dividend — NXC or BLK or IVZ or TROW or BEN?
In this comparison, TROW (4.
9% yield), BEN (4. 3% yield), IVZ (3. 1% yield), BLK (1. 9% yield) pay a dividend. NXC does not pay a meaningful dividend and should not be held primarily for income.
09Is NXC or BLK or IVZ or TROW or BEN better for a retirement portfolio?
For long-horizon retirement investors, Nuveen California Select Tax-Free Income Portfolio (NXC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
04)). Invesco Ltd. (IVZ) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NXC: +13. 1%, IVZ: +22. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NXC and BLK and IVZ and TROW and BEN?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NXC is a small-cap quality compounder stock; BLK is a mid-cap quality compounder stock; IVZ is a mid-cap income-oriented stock; TROW is a mid-cap deep-value stock; BEN is a mid-cap income-oriented stock. BLK, IVZ, TROW, BEN pay a dividend while NXC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.